Blood cancer Patients' vaccine response under the microscope
NCT ID NCT05170399
First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 6 times
Summary
This study looks at how well vaccines for flu, COVID-19, shingles, hepatitis B, and pneumonia work in people with certain blood cancers like chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas. Researchers will measure immune responses through blood samples before and after vaccination. Up to 500 adults will participate, and some may pause their cancer treatment temporarily to see if that improves vaccine effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vaccines (influenza, shingles, pneumococcal, hepatitis B, COVID-19)
- What this could lead to
- If successful, this could help doctors recommend better vaccine schedules for people with blood cancers, potentially improving protection against preventable diseases.
- What could go wrong
- This is an observational study, not testing a new treatment. Results may not apply to all blood cancer patients, and vaccine responses may still be weak in some individuals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a targeted drug boost standard therapy for a rare lymphoma?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a targeted drug boost standard chemo for a rare blood cancer?
- Can a drug duo outsmart resistant lymphomas?
- Can a second CAR T-Cell infusion beat lymphoma that returns?